This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Close
Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • Avastin® (bevacizumab)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼(pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozyltrek▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Immunology
      • RoACTEMRA® (tocilizumab)
      • Haematology
      • Gazyvaro® (obinutuzumab)
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib)
      • Avastin® (bevacizumab)
      • Esbriet® (pirfenidone)
      • GAZYVARO® (obinutuzumab)
      • HEMLIBRA®▼(emicizumab)
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab)
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin)
      • RoACTEMRA® (tocilizumab) RA/GCA
      • RoACTEMRA® (tocilizumab) pJIA/sJIA
      • RoACTEMRA® (tocilizumab) CRS
      • Rozlytrek® ▼(entrectinib)
      • Tecentriq®▼ (atezolizumab) HCC
      • Tecentriq®▼ (atezolizumab) Lung Cancer
      • Tecentriq®▼ (atezolizumab) mTNBC
      • Tecentriq®▼ (atezolizumab) mUC
    • Adverse Events Reporting
      Adverse Events Reporting Overview
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.

    HEMLIBRA

     

     

    For routine prophylaxis of bleeding episodes in patients of all ages with congenital haemophilia A, classified as severe or with Factor VIII (FVIII) inhibitors1

    • HEMLIBRA®▼ (emicizumab)
    • Prescribing Info
    • Efficacy
      • Efficacy RCTs
      • Efficacy Non-RCTs
      • Study Designs
    • Safety
      • Pharmacovigilance
    • Dosing
    • PK and MOA
    • Publications
    • Surgery
      • Minor Surgery
      • Major Surgery
    • Lab Assays
      • Haemophilia A and Laboratory Tests
    • Horizons Meetings
    • More
      • Prescribing Info
      • Efficacy
      • Safety
      • Dosing
      • PK and MOA
      • Publications
      • Surgery
      • Lab Assays
      • Horizons Meetings

    You are here:

    1. Roche Medicines
    2. Rare Diseases
    3. HEMLIBRA®▼ (emicizumab)
    4. Efficacy
    5. Study Designs

    HAVEN 1 and HAVEN 3 were randomised clinical trials, HAVEN 2 and HAVEN 4 were non-randomised clinical trials. Randomised study designs are listed before non-randomised study designs.

    HEMLIBRA was evaluated in HAVEN – an extensive clinical trial programme in patients with congenital haemophilia A1–5

    HEMLIBRA
    • All HAVEN studies met their bleed rate endpoints2-5

    HAVEN 3 evaluated HEMLIBRA prophylaxis in severe congenital haemophilia A (N=152)2

    • Randomised, multicentre, open-label, phase III study, in adult and adolescent males2
    • HEMLIBRA every week (QW) and every two weeks (Q2W) were compared with episodic FVIII; an intra-individual comparison also evaluated HEMLIBRA QW vs. prior FVIII prophylaxis2
    • HEMLIBRA dose: 3.0 mg/kg/QW for 4 weeks; 1.5 mg/kg/QW or 3.0 mg/kg/Q2W thereafter2

    Related links:

    • Long-term efficacy
    • Efficacy RCTs
    • Efficacy non-RCTs
    • HAVEN 3 study design details

      Males with severe congenital haemophilia A (endogenous FVIII activity, <1%) without inhibitors, ≥12 years; treated with episodic FVIII or FVIII prophylaxis* in the prior 24 weeks (N=152).2,6

      HAVEN 3 study design details

      *At least five bleeding events in the prior 24 weeks required for episodic FVIII. No bleed requirements with prior prophylaxis.6

      Patients in Arm C received no prophylaxis; after completing ≥24 weeks in the trial they could receive HEMLIBRA prophylaxis Q2W (and remain in Arm C). For all participants, additional FVIII was administered at investigator-determined doses for breakthrough bleeding.

      Primary efficacy endpoint: treated bleeds at ≥24 weeks in Arm A vs. C and Arm B vs. C.2

      Two patients (one in Arm A and one in Arm C) were lost to follow-up and not treated. These patients were included in the primary efficacy analysis, but not in the surgery analysis.2,7

      The non-interventional study (NIS) followed patients receiving FVIII prophylaxis (n=48) and prospectively collected data on bleeds and FVIII administration. The availability of granular data enabled paired analyses, using identical definitions and methodologies to HAVEN 3. Each patient received adequate prophylaxis, as determined by investigators. The NIS resulted in an intra-individual comparison analysis – part of HAVEN 3, Arm D, which was controlled for inter-individual variability (e.g. bleeding characteristics, risk factors for bleeds and patient recognition of bleeds).2,8

      Data cut-off: 15 September 2017.

    For full study details please refer to the 
     HAVEN 3 publication

    • HAVEN 3 participant demographic and clinical characteristics
      HAVEN 3 participant demographic and clinical characteristics

      *All values based on electronic case-report forms. Does not include data from the non-interventional study.6

      †In Arm B, one patient reported ‘Other’ as the product used. Therefore, percentages based on 34 participants in Arm B and 151 participants in the Total column.6

    HAVEN 1 evaluated HEMLIBRA prophylaxis in congenital haemophilia A with FVIII inhibitors (N=109)3

    • Randomised, multicentre, open-label, phase III study, in adult and adolescent males3
    • HEMLIBRA QW was compared with episodic bypassing agents (BPAs); an intra-individual comparison
      also evaluated HEMLIBRA QW vs. prior BPA prophylaxis3
    • HEMLIBRA dose: 3.0 mg/kg/QW for 4 weeks; 1.5 mg/kg/QW thereafter3
    • HAVEN 1 study design details

      Males with congenital haemophilia A with FVIII inhibitors, ≥12 years, ≥40 kg; treated with episodic BPAs or BPA prophylaxis in the prior 24 weeks (N=109).3,9

      HAVEN 1 study design details

      Primary efficacy endpoint: treated bleeds at ≥24 weeks in Arm A vs. B.

      Patients in Arm B received no prophylaxis and no subcutaneous control injections; after completing ≥24 weeks in the trial they could receive HEMLIBRA prophylaxis QW (and remain in Arm B). All participants receiving HEMLIBRA could receive episodic treatment with BPAs for breakthrough bleeding, as needed.

      One patient in Arm A discontinued prior to treatment; this patient was included in the primary efficacy analysis and the surgical analysis. Since the data cut-off for the primary analysis, an additional four patients were enrolled and included in the surgery analysis.7,9

      Arm C included patients from the intra-individual comparison from the non-interventional study (NIS, n=24). This prospective NIS evaluated real-world bleeding and safety data. Eligible patients were subsequently able to participate in HAVEN 1. Arm D included NIS participants enrolled after randomisation deadline and included in the safety analysis (n=7 at cut-off).3 Data from Arms C and D are not presented here; for details, please refer to the HAVEN 1 publication

      Data cut-off: 25 October 2016.

    For full study details please refer to the 
    HAVEN 1 publication

    • HAVEN 1 participant demographic and clinical characteristics
      HAVEN 1 participant demographic and clinical characteristics

      *All values based on electronic case-report forms and not on data from the NIS.3

      †All participants had a FVIII inhibitor titre of ≥5.0 Bethesda units/ml.3

    HAVEN 2 evaluated HEMLIBRA prophylaxis in congenital haemophilia A with FVIII inhibitors (N=88)4

    • Non-randomised, multicentre, open-label, phase III study, in paediatric males4
    • HEMLIBRA dose: 3.0 mg/kg/QW for 4 weeks; 1.5 mg/kg/QW, 3.0 mg/kg/Q2W or 6.0 mg/kg/Q4W thereafter4
    • HAVEN 2 study design details

      Males with congenital haemophilia A with FVIII inhibitors, <12 years*; treated with episodic BPAs or BPA prophylaxis in the prior 24 weeks (N=88).4

      HAVEN 2 study design details

      *Participants aged <2 years were enrolled after results of the interim analysis if they had a high medical need (n=8). Participants aged 12–17 years and <40 kg were included in Arm A, but not in the efficacy analysis (n=3).4

      HAVEN 2 was designed as a descriptive study with no defined primary or secondary endpoints. Efficacy endpoints included the rate of treated bleeding events.4

      The Q2W and Q4W cohorts (Arms B and C) were added later for characterisation of PK, to support extrapolation. No patients <2 years old or 12–17 years old could enrol in these cohorts.4

      Data cut-off: 30 April 2018.

    For full study details please refer to the 
    HAVEN 2 publication

    • HAVEN 2 participant demographic and clinical characteristics
      HAVEN 2 participant demographic and clinical characteristics

    HAVEN 4 evaluated HEMLIBRA prophylaxis in congenital haemophilia A, classified as severe or with FVIII inhibitors (N=48)5

    • Non-randomised, multicentre, open-label, phase III study, in adult and adolescent males5
    • HEMLIBRA dose: 3.0 mg/kg/QW for 4 weeks, followed by 6.0 mg/kg/Q4W thereafter5
    • HAVEN 4 study design details

      Males with congenital haemophilia A, classified as severe or with FVIII inhibitors, ≥12 years; treated with BPAs or FVIII in the prior 24 weeks (N=48).5

      HAVEN 4 study design details

      Patients in the initial run-in cohort (n=7) received HEMLIBRA 6.0 mg/kg/Q4W for ≥24 weeks to assess safety and establish pharmacokinetics of the regimen.

      Patients in the expansion cohort (n=41) were included in the efficacy analysis: treated annualised bleed rate (ABR). At the time of analysis all patients had received ≥24 weeks treatment.

      Data cut-off: 15 December 2017.

    For full study details please refer to the 
    HAVEN 4 publication

    • HAVEN 4 participant demographic and clinical characteristics
      HAVEN 4 participant demographic and clinical characteristics

       *Includes one patient with mild haemophilia, inhibitors (32 Bethesda units/ml) and <1% FVIII activity at study entry.5

    BPA, bypassing agent; FVIII, Factor VIII; PK, pharmacokinetics; QW, every week; Q2W, every 2 weeks; Q4W, every 4 weeks.

    References:

    1. HEMLIBRA Summary of Product Characteristics.
    2. Mahlangu J et al. N Eng J Med 2018;379:811–22.
    3. Oldenburg J et al. N Eng J Med 2017;377:809-18.
    4. Young G et al. Blood 2019 [Epub ahead of print].
    5. Pipe S et al. Lancet Haematol 2019;6(6):e295–e305.
    6. Mahlangu J et al. N Eng J Med 2018;379:811–22 [Supplementary Appendix].
    7. Santagostino E et al. ISTH 2019 [Oral Presentation].
    8. Mahlangu J et al. WFH 2018;854 [Oral Presentation].
    9. Oldenburg J et al. N Eng J Med 2017;377:809-18 [Supplementary Appendix].
    10. Pipe S et al. WFH 2018 [Oral Presentation].


    M-GB-00001037
    Date of preparation: August 2020

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2021 Roche Products Limited
    • 19.01.2021
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. ▼Additional monitoring: Medicinal products associated with this symbol are subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. For biological medicines, healthcare professionals should report adverse reactions by brand name and batch number. This is a promotional website intended for HCPs, designed, built and funded by Roche Products Ltd. Commentary and other materials, including external links, posted on this site are not intended to amount to advice on which reliance should be placed. We therefore disclaim all liability and responsibility arising from any reliance placed on such materials by any visitor to our site, or by anyone who may be informed of any of its contents. M-GB-00002434 Date of Preparation January 2021.